Navigation Links
Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009
Date:10/29/2008

last year.

-- Non-GAAP operating performance, which excludes non-cash charges for

share-based compensation under SFAS 123 (R), and depreciation and

amortization expenses, improved from a loss of approximately $0.6

million and $1.0 million, respectively, for the three and six months

ended September 30, 2007, to a (loss) gain of approximately ($98,000)

and $8,000, respectively for the three and six months ended September

30, 2008. The improvement in non-GAAP operating performance is

attributed to the increase in sales and an improvement in gross margin,

partially offset by an increase in cash operating expenses.

-- At September 30, 2008, cash and cash equivalents, and short-term

investments were $9.0 million compared with $9.2 million at June 30,

2008 and $10.1 million at March 31, 2008.

"Earlier this month, we announced the first patient enrollment in a new, multicenter clinical study that will support our U.S. reimbursement efforts, and is part of a very focused strategy to solidify reimbursement coverage for PTNS," continued Mr. Kaysen. "We are making impressive progress with center and patient enrollment in the new study which compares the Urgent PC system treatment against non-active treatment (placebo or sham treatment). This study design was suggested by professional associations that help to educate third party insurance carriers establish reimbursement for procedures. We anticipate applying to the American Medical Association for a specific "listed" CPT reimbursement code for Urgent PC treatments once the data is compiled and analyzed.

"Meanwhile, we have implemented a comprehensive program designed to educate medical directors of insurance carriers around the country. Physicians using Urgent PC are communicating their successes to these medical directors. In addition, we are in active communication with professional associations who are involv
'/>"/>

SOURCE Uroplasty, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Uroplasty to Present at the Noble Financial Fourth Annual Equity Conference
2. Uroplasty to Host First Quarter Conference Call on July 31
3. Uroplasty Joins the Russell Microcap Index
4. Uroplasty Reports Record Growth for the Fourth Quarter and Fiscal Year 2008
5. Uroplasty to Host Fourth Quarter and Year End Conference Call on June 3
6. Uroplasty to Highlight Urgent PC System at American Urological Association 2008 Annual Meeting
7. Uroplasty Plans to Double Sales Force During Fiscal 2009
8. Uroplasty, Inc. Reports Presentations of Urgent(R) PC Studies at the 2008 Society of Urologic Nurses and Associates Annual Symposium
9. Uroplasty to Present at ROTH Capital Partners 20th Annual OC Growth Stock Conference
10. Uroplasty Expands Marketing Program for Urology Practices
11. Uroplasty, Inc. Announces Pricing of a Public Offering of Its Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 2Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 3Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 4Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 5Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 6Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 7Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 8Remote Technologies Improve Patient Care, Viable Alternative to Intensivist Shortage 2Remote Technologies Improve Patient Care, Viable Alternative to Intensivist Shortage 3Veran Medical Receives FDA Clearance to Market Electromagnetic Navigated Bronchoscopy Product: The SPiN Drive(TM) System 2Study Shows GSKs Novel Diabetes Treatment SYNCRIA 28R 29 28albiglutide 29 Improves Glucose Control and Reduces Weight 4549 1Study Shows GSKs Novel Diabetes Treatment SYNCRIA 28R 29 28albiglutide 29 Improves Glucose Control and Reduces Weight 4549 2Study Shows GSKs Novel Diabetes Treatment SYNCRIA 28R 29 28albiglutide 29 Improves Glucose Control and Reduces Weight 4549 3Orange County Laser Surgeon Nissan Pilest Tapped as Keynote Speaker at Fraxel 26amp 3B Thermage User Forum Held at Beckman Laser Institute 12498 1Orange County Laser Surgeon Nissan Pilest Tapped as Keynote Speaker at Fraxel 26amp 3B Thermage User Forum Held at Beckman Laser Institute 12498 2Orange County Laser Surgeon Nissan Pilest Tapped as Keynote Speaker at Fraxel 26amp 3B Thermage User Forum Held at Beckman Laser Institute 12498 32009 Houston Juneteenth Multicultural Health Festival Becomes Largest Health Event in Texas 3A Festival Moves Indoors to the Cool George R Brown 48107 12009 Houston Juneteenth Multicultural Health Festival Becomes Largest Health Event in Texas 3A Festival Moves Indoors to the Cool George R Brown 48107 2